MedReleaf Signs Research Agreement with BioPharma Services
MedReleaf (TSX:LEAF) announced an exclusive agreement with BioPharma Services to conduct clinical research for cannabis and its derived product.
As quoted in the press release:
BioPharma will provide medical, clinical, pharmacological and lab expertise to expedite MedReleaf’s product strategy to support in-market products as well as products under development for registration in Canadian and international markets.
BioPharma is well positioned to accelerate MedReleaf’s product development and clinical research programs through their international experience in running early phase clinical trials. MedReleaf and Biopharma will jointly provide scientific and regulatory guidance to clinical research studies supporting MedReleaf’s product launches in the months to come.
“This strategic alliance sets us apart in the clinical research and development space for cannabis and cannabis derived products and will facilitate much needed cannabinoid therapies to assist in the treatment of pain, inflammatory conditions, mental health, palliative care and underserved therapeutic areas,” said Angelo Fefekos, Senior Vice President Clinical Affairs and Quality Assurance at MedReleaf.
Click here to read the full press release.
The post MedReleaf Signs Research Agreement with BioPharma Services appeared first on Investing News Network.